Tissue Study Validates MR Perfusion Technology
Monday, 22 June 2009 09:09 | 
| Company News - Imaging Biometrics, LLC |
Imaging Biometrics IB Neuro shows high correlation with tissue analysis
A preliminary study, led by cancer researchers at Barrow Neurological Institute at St. Joseph’s Hospital and Medical Center (BNI-SJHMC) and Imaging Biometrics LLC (IB), has validated a magnetic resonance imaging perfusion (pMRI) technology with stereotactic tissue biopsy results. Using the proprietary technology contained in IB Neuro, an accuracy of 95.6% was obtained when distinguishing tumor from post treatment radiation effects (PTRE). This makes IB Neuro the only perfusion analysis product directly validated with spatially accurate tissue samples.
IB Neuro uses dynamic susceptibility contrast (DSC) perfusion algorithms to provide information about blood volume and blood flow in the brain. These critical perfusion parameters are valuable for detecting the growth of new tumor blood vessels (angiogenesis). This angiogenic information allows clinicians to more accurately diagnose tumor aggressiveness and potentially predict responses to anti-tumor therapies. However, this rich information has not been widely accepted due to the lack of a reliable and standardized method for use in routine clinical patients.
Researchers at BNI-SJHMC have developed a unique method of correlating imaging measurements with biopsied tumor samples, which has shown promise in validating techniques using IB Neuro. Directly comparing pMRI measurements with brain tumor tissue biopsy samples could result in a long awaited standardized pMRI approach. This technology can potentially lead to safer, more efficient, and more accurate diagnosis and treatment of glioma patients.
Planning is underway for a larger study to verify the accuracy obtained. “The preliminary results are very promising”, said Michael Schmainda, IB’s President and CEO, “We are confident the results of the larger study will accelerate the clinical adoption of pMRI”.
About Barrow and St. Joseph’s
Barrow Neurological Institute at St. Joseph’s Hospital and Medical Center has lead the way in the development of cutting-edge diagnosis, treatment and neurosurgical procedures for patients with brain tumors. Every year, Barrow treats thousands of patients with brain tumors, including some of the most difficult cases in the world.
About Imaging Biometrics LLC
Imaging Biometrics develops and provides visualization and analytical solutions that enable clinicians to better diagnose and treat diseases with greater confidence. Through close collaboration with top researchers and clinicians, sophisticated advancements are translated into platform-independent software plug-ins which can extend the base functionality of workstations, imaging systems, PACS, or medical viewers. By design, IB Neuro, advanced visualization software seamlessly integrates into routine clinical workflows. For more information about Imaging Biometrics, visit the company’s website at www.imagingbiometrics.com.
Source: Imaging Biometrics
A preliminary study, led by cancer researchers at Barrow Neurological Institute at St. Joseph’s Hospital and Medical Center (BNI-SJHMC) and Imaging Biometrics LLC (IB), has validated a magnetic resonance imaging perfusion (pMRI) technology with stereotactic tissue biopsy results. Using the proprietary technology contained in IB Neuro, an accuracy of 95.6% was obtained when distinguishing tumor from post treatment radiation effects (PTRE). This makes IB Neuro the only perfusion analysis product directly validated with spatially accurate tissue samples.
IB Neuro uses dynamic susceptibility contrast (DSC) perfusion algorithms to provide information about blood volume and blood flow in the brain. These critical perfusion parameters are valuable for detecting the growth of new tumor blood vessels (angiogenesis). This angiogenic information allows clinicians to more accurately diagnose tumor aggressiveness and potentially predict responses to anti-tumor therapies. However, this rich information has not been widely accepted due to the lack of a reliable and standardized method for use in routine clinical patients.
Researchers at BNI-SJHMC have developed a unique method of correlating imaging measurements with biopsied tumor samples, which has shown promise in validating techniques using IB Neuro. Directly comparing pMRI measurements with brain tumor tissue biopsy samples could result in a long awaited standardized pMRI approach. This technology can potentially lead to safer, more efficient, and more accurate diagnosis and treatment of glioma patients.
Planning is underway for a larger study to verify the accuracy obtained. “The preliminary results are very promising”, said Michael Schmainda, IB’s President and CEO, “We are confident the results of the larger study will accelerate the clinical adoption of pMRI”.
About Barrow and St. Joseph’s
Barrow Neurological Institute at St. Joseph’s Hospital and Medical Center has lead the way in the development of cutting-edge diagnosis, treatment and neurosurgical procedures for patients with brain tumors. Every year, Barrow treats thousands of patients with brain tumors, including some of the most difficult cases in the world.
About Imaging Biometrics LLC
Imaging Biometrics develops and provides visualization and analytical solutions that enable clinicians to better diagnose and treat diseases with greater confidence. Through close collaboration with top researchers and clinicians, sophisticated advancements are translated into platform-independent software plug-ins which can extend the base functionality of workstations, imaging systems, PACS, or medical viewers. By design, IB Neuro, advanced visualization software seamlessly integrates into routine clinical workflows. For more information about Imaging Biometrics, visit the company’s website at www.imagingbiometrics.com.
Source: Imaging Biometrics
